AngioDynamics (ANGO) Misses Q3 EPS by 3c, Revenues Miss; Reiterates FY19 EPS/Revenue Mid-Point Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. META
4. DPZ
5. IBM
6. CNC
7. KFY
8. SPY
9. MU
10. ENRD

Go back to AngioDynamics (ANGO) Misses Q3 EPS by 3c, Revenues Miss; Reiterates FY19 EPS/Revenue Mid-Point Guidance Below Consensus

AngioDynamics Reports Fiscal 2019 Third Quarter Financial Results

April 2, 2019 7:00 AM EDT

Fiscal 2019 Third Quarter Highlights

Net sales of $86.3 million, an increase of 3.0% year over year Gross margin declined 10 basis points year over year to 54.1% GAAP EPS of $0.02 per share; adjusted EPS of $0.19 per share Cash provided by operations of $8.3 million; capital expenditures of $0.9 million Received unconditional IDE approval from the FDA to initiate NanoKnife® DIRECT Clinical Study Won patent infringement dispute with Bard

... More